HER2 heterogeneity is a poor prognosticator for HER2-positive gastric cancer

Figure 3 Clinical response for patients with or without intratumoral human epidermal growth factor receptor 2 heterogeneity. Tumor shrinkage (left) and clinical response (right) was evaluated by RECIST ver. 1.1 for 58 patients who have measurable metastatic lesions. ORR was 79.5% in the Homo group, which was significantly higher than that in the Hetero group (35.7%, P = 0.002). CR: Complete response; PR: Partial response; SD: Stable disease; PD: Progressive disease; ORR: Overall response rate (CR plus PR).